127 related articles for article (PubMed ID: 11167671)
1. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
Jones K; Hoggard PG; Khoo S; Maher B; Back DJ
Br J Clin Pharmacol; 2001 Jan; 51(1):99-102. PubMed ID: 11167671
[TBL] [Abstract][Full Text] [Related]
2. Intracellular accumulation of human immunodeficiency virus protease inhibitors.
Khoo SH; Hoggard PG; Williams I; Meaden ER; Newton P; Wilkins EG; Smith A; Tjia JF; Lloyd J; Jones K; Beeching N; Carey P; Peters B; Back DJ
Antimicrob Agents Chemother; 2002 Oct; 46(10):3228-35. PubMed ID: 12234849
[TBL] [Abstract][Full Text] [Related]
3. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
Boffito M; Hoggard PG; Reynolds HE; Bonora S; Meaden ER; Sinicco A; Di Perri G; Back DJ
Br J Clin Pharmacol; 2002 Sep; 54(3):262-8. PubMed ID: 12236846
[TBL] [Abstract][Full Text] [Related]
4. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
Jones K; Hoggard PG; Sales SD; Khoo S; Davey R; Back DJ
AIDS; 2001 Apr; 15(6):675-81. PubMed ID: 11371681
[TBL] [Abstract][Full Text] [Related]
5. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
6. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
King JR; Gerber JG; Fletcher CV; Bushman L; Acosta EP
AIDS; 2005 Jul; 19(10):1059-63. PubMed ID: 15958837
[TBL] [Abstract][Full Text] [Related]
7. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors.
Zhang XQ; Schooley RT; Gerber JG
J Infect Dis; 1999 Dec; 180(6):1833-7. PubMed ID: 10558938
[TBL] [Abstract][Full Text] [Related]
8. Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.
Armbruster C; Vorbach H; Steindl F; El Menyawi I
J Antimicrob Chemother; 2001 Apr; 47(4):487-90. PubMed ID: 11266428
[TBL] [Abstract][Full Text] [Related]
9. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
10. Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.
Diker B; Janneh O; van Heeswijk RP; Copeland KF
Drug Metab Lett; 2010 Dec; 4(4):241-5. PubMed ID: 20690898
[TBL] [Abstract][Full Text] [Related]
11. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
[TBL] [Abstract][Full Text] [Related]
13. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
Buss N; Snell P; Bock J; Hsu A; Jorga K
Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Chi J; Jayewardene AL; Stone JA; Motoya T; Aweeka FT
J Pharm Biomed Anal; 2002 Oct; 30(3):675-84. PubMed ID: 12367693
[TBL] [Abstract][Full Text] [Related]
15. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
17. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S; Buclin T; Décosterd LA; Telenti A; Furrer H; Lee BL; Biollaz J; Eap CB;
Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
[TBL] [Abstract][Full Text] [Related]
18. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Sayer JM; Louis JM
Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Eagling VA; Back DJ; Barry MG
Br J Clin Pharmacol; 1997 Aug; 44(2):190-4. PubMed ID: 9278209
[TBL] [Abstract][Full Text] [Related]
20. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Chai H; Yang H; Yan S; Li M; Lin PH; Lumsden AB; Yao Q; Chen C
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):12-9. PubMed ID: 16123675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
